Business
Director Disclosure Update
Director Disclosure Update.
About this update from Valirx Plc
[{"type":"text","content":"\n\n \nValiRx PLC\n(\"ValiRx\" or the \"Company\")\n \nDirector Disclosure Update\nLondon, UK - ValiRx Plc (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, issues the following disclosure in relation to Martin Gouldstone, Chairman of the Company pursuant to AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies.\nOncimmune Holdings PLC, a company which Martin Gouldstone is a Director, recently announced its intention to appoint administrators.\nThere is nothing further to disclose in respect of Schedule 2(g) of the AIM Rules for Companies.\nThe Directors of the Company take responsibility for this announcement.\n \n*** ENDS ***\nEngage with the ValiRx management team directly by asking questions, watching video summaries and seeing what other shareholders have to say. Navigate to our Interactive Investor hub here: https://valirx.com/s/cc8ef3\nFor more information, please contact:\n \n\n\n\n\nInvestor questions on this announcement\nWe encourage all investors to share questions\non this announcement via our investor hub\n\n\nhttps://valirx.com/link/oPB60P\n \n\n\n\n\nValiRx plc\n \nDr Mark Eccleston, CEO\n \n \n\n\nTel: +44 115 784 0025\nwww.valirx.com\[email protected]\n \n \n\n\n\n\nCairn Financial Advisers LLP (Nominated Adviser)\n \nLiam Murray / Ludovico Lazzaretti\n \n\n\nTel: +44 (0) 20 7213 0880\n\n\n\n\nShard Capital Partners LLP (Sole Broker)\n \nDamon Heath\n \n\n\nTel: +44 (0) 20 7186 9000\n\n\n\n\nV Formation (Public Relations)\n \nLucy Wharton - Senior PR Executive\nSue Carr - Director\n \n\n\n+44 (0) 115 787 0206\nwww.vformation.biz\n \[email protected]\[email protected]\n\n\n\n\n \nSubscribe to our news alert service: https://valirx.com/s/f298d1\n \nNotes for Editors\nAbout ValiRx\nValiRx is a life science company focused on early-stage cancer therapeutics and women's health, accelerating the translation of innovative science into impactful medicines to improve patient lives.\nValiRx provides the scientific, financial, and commercial framework for enabling rapid translation of innovative science into clinical development.\nUsing its extensive and proven experience in research and drug development, the team at ValiRx selects and incubates promising nov...